Topic: butyrylcholinesterase

Recently, a central role of butyrylcholinesterase (BChE) in pathogenesis of obesity has been proposed. As BChE was shown to inactivate a hunger hormone, ghrelin, it has been suggested to control appetite and glucose metabolism by regulating ghrelin signaling in hypothalamus. The aim of our study was therefore to investigate the relationship between obesity induced by high-fat/high-fructose diet and BChE activity. We studied impact of the diet-induced obesity on serum BChE and vise-versa an effect of BChE inhibition on obesity development. Adults male Wistar rats were fed with standard or high-

Depression, a prevalent psychiatric disorder that significantly impacts quality of life. Cholinergic transmission dysregulation potentially contributes to emotional and behavioral disturbances. While acetylcholinesterase is commonly studied in depression, the role of butyrylcholinesterase (BChE) remains unclear. We recently developed the butyrylcholinesterase (BChE)-activatable molecular sensor (BCC) for real-time visualization of BChE activity, demonstrating its efficiency in vitro and in tumor-bearing mice. In this translational study, we employed BCC to investigate BChE changes in depressio

Imbalance of the autonomic nervous system is implicated in numerous cardiovascular pathologies. Enhanced cholinergic signalling in the heart has therapeutic potential and cholinesterase (ChE) inhibitors are under consideration for treating cardiovascular pathologies. Nevertheless, information about ChE in heart and their role in cardiac physiology are sparse. Here, we characterize the molecular composition, localization, and physiological functions of ChE in the mouse heart. Biochemical, microscopic, and physiological experiments were used to analyse ChE in mutant mice hearts lacking different

Quercetin is a polyphenolic flavonoid compound with a proven wide range of biological activities including neuroprotective effects in neuronal injury/neurodegenerative disease models which is related with its high antioxidant properties. However, due to its low water-solubility, poor bioavailability, rapid clearance, instability, and inability to cross the blood–brain barrier (BBB) its potential application for treatment of central nervous system (CNS) disease is limited. Tetrahydroisoquinoline (THIQ) scaffold appears in many drugs’ structures applied in diverse medical applications. Recent re

Several therapeutic targets have been identified to counteract the cognitive decline of Alzheimer's disease (AD). One of the recent approaches, which takes account the multifactorial origin of AD, is pleiotropic drugs. Multi-targeted directed ligands are designed to target different molecular causes involved in the pathogenesis of AD. A novel compound, acting as a prodrug and able of both selectively inhibiting butyrylcholinesterase and secondarily interacting with serotonin subtype 4 receptor, has therefore been developed. The first step of the project was to assess pharmacological screening